Ronald Rodriguez1,2, Shawn E Lupold1,2, Ping Wu1, Lori J Sokoll1,2,3, Tarana A Kudrolli1, Wasim H Chowdhury1, Rong Ma1, Minzhi M Liu1. 1. The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine, 600 N Wolfe St, Baltimore, MD 21287. 2. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231. 3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Abstract
BACKGROUND: Circulating tumor cells (CTCs) hold great promise as biomarkers and are a direct source of tumor cells through a simple blood draw. However, CTCs are rare and their detection requires sensitive and specific methods to overcome the overwhelming hematocyte population. Therefore, CTC detection remains technically challenging. METHODS: An assay was developed for detecting viable and tissue-specific CTCs using a tropism-enhanced and conditionally replicating reporter adenovirus (CTC-RV). Adenoviral replication was made prostate-specific by placing the E1A gene under the control of the probasin promoter and prostate-specific antigen enhancer (PSE-PBN). Viral tropism was expanded through capsid-displayed integrin targeting peptides. A secreted reporter, humanized Metridia Luciferase (hMLuc), was engineered for expression during the major late phase of viral replication. The assay involves red blood cell lysis, cell collection, viral infection, and subsequent quantification of reporter activity from cellular media. Assay and reporter stability, cell specificity and sensitivity were evaluated in cell dilution models in human blood. RESULTS: A conditionally replicating prostate-selective adenovirus reporter and CTC assay system were generated. The secreted reporter, MLuc, was found to be stable for at least 3 days under assay conditions. CTC detection, modeled by cell dilution in blood, was selective for androgen receptor positive prostate cancer (PCa) cells. Serial dilution demonstrated assay linearity and sensitivity to as few as three cells. Prostate cancer cell viability declined after several hours in anticoagulated blood at ambient temperatures. CONCLUSIONS: Conditionally replicative adenoviral vectors and secreted reporters offer a functional method to detect viable CTCs with cell specificity and high sensitivity.
BACKGROUND: Circulating tumor cells (CTCs) hold great promise as biomarkers and are a direct source of tumor cells through a simple blood draw. However, CTCs are rare and their detection requires sensitive and specific methods to overcome the overwhelming hematocyte population. Therefore, CTC detection remains technically challenging. METHODS: An assay was developed for detecting viable and tissue-specific CTCs using a tropism-enhanced and conditionally replicating reporter adenovirus (CTC-RV). Adenoviral replication was made prostate-specific by placing the E1A gene under the control of the probasin promoter and prostate-specific antigen enhancer (PSE-PBN). Viral tropism was expanded through capsid-displayed integrin targeting peptides. A secreted reporter, humanized Metridia Luciferase (hMLuc), was engineered for expression during the major late phase of viral replication. The assay involves red blood cell lysis, cell collection, viral infection, and subsequent quantification of reporter activity from cellular media. Assay and reporter stability, cell specificity and sensitivity were evaluated in cell dilution models in human blood. RESULTS: A conditionally replicating prostate-selective adenovirus reporter and CTC assay system were generated. The secreted reporter, MLuc, was found to be stable for at least 3 days under assay conditions. CTC detection, modeled by cell dilution in blood, was selective for androgen receptor positive prostate cancer (PCa) cells. Serial dilution demonstrated assay linearity and sensitivity to as few as three cells. Prostate cancer cell viability declined after several hours in anticoagulated blood at ambient temperatures. CONCLUSIONS: Conditionally replicative adenoviral vectors and secreted reporters offer a functional method to detect viable CTCs with cell specificity and high sensitivity.
Authors: Jose G Moreno; M Craig Miller; Steve Gross; W Jeffrey Allard; Leonard G Gomella; Leon W M M Terstappen Journal: Urology Date: 2005-04 Impact factor: 2.649
Authors: Ignacio Cruz; Juana Ciudad; Juan Jesús Cruz; Manuel Ramos; Alberto Gómez-Alonso; Juan Carlos Adansa; Cesar Rodríguez; Alberto Orfao Journal: Am J Clin Pathol Date: 2005-01 Impact factor: 2.493
Authors: B T Chen; R D Loberg; C K Neeley; S M O'Hara; S Gross; G Doyle; R L Dunn; L M Kalikin; K J Pienta Journal: Urology Date: 2005-03 Impact factor: 2.649
Authors: Eric J Small; Michael A Carducci; James M Burke; Ron Rodriguez; Lawrence Fong; Lynn van Ummersen; D C Yu; Junko Aimi; Dale Ando; Peter Working; David Kirn; George Wilding Journal: Mol Ther Date: 2006-05-09 Impact factor: 11.454
Authors: Jan E Carette; Harm C A Graat; Frederik H E Schagen; Mohamed A I Abou El Hassan; Winald R Gerritsen; Victor W van Beusechem Journal: J Gene Med Date: 2005-08 Impact factor: 4.565